Having trouble accessing articles? Reset your cache.

Sept. 6 Financial Quick Takes: Turning Point, uniQure raise follow-ons; plus Autolus, Frequency, ADC

Turning Point, uniQure price follow-ons
Turning Point Therapeutics Inc. (NASDAQ:TPTX) and uniQure N.V. (NASDAQ:QURE) raised a total of nearly $428 million in follow-on offerings priced late Thursday.

Days after a readout from the first part of a Phase I/II trial of its lead candidate repotrectinib, Turning Point raised $202.5 million through the sale

Read the full 516 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers